熱門資訊> 正文

ADC Therapeutics公布2025年初步收入约为7300万美元

2026-01-09 05:25

ADC Therapeutics Ltd(ADCT) 0

ADC Therapeutics SA (ADCT) said on Thursday it expects preliminary unaudited net product revenue of about $22 million for the fourth quarter of 2025 and approximately $73 million for the full year.
The company said it ended 2025 with cash and cash equivalents of about $261 million, which it expects will fund operations at least into 2028.
ADC Therapeutics said enrollment in its LOTIS-7 trial is expected to be completed in the first half of 2026, with topline data from the LOTIS-5 Phase 3 trial anticipated in the second quarter of 2026.
ADCT +1.96% after hours to $3.64.
Source: Press Release

More on ADC Therapeutics

ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL - Slideshow
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Transcript
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones
ADC Therapeutics Q3 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。